Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

ed on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries, including England, Wales, Italy, Finland, Ireland, the Netherlands and Spain; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study, including the timing of availability of such results, and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... call and webcast to begin after markets close at 2:00 p.m. PT ... ... Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- ... the period ended,September 27, 2008 after the market closes on Monday, October ...
... Oct. 15 PURE Bioscience (Nasdaq:,PURE), creators of ... revenues for the fiscal year ended July 31, ... with $336,400 in the,prior fiscal year. The Company ... or $(0.24) per share, compared with a loss ...
... Agency Expanding Industry Connections, MOUNTAINSIDE, N.J., Oct. ... medical education company,today announced the hiring of Todd ... leverage his experience in medical education and,publishing as ... L&M, he,served as Manager of Publication Sales at ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... changes, might in fact be driven by a simple and ... range of specieshappen to share, according to new research. ... suggests that knowledge of a species, genes and how ... could be used to determine a predictable evolutionary pattern ...
... University of South Florida researchers have identified a genetic ... understanding and preventing a condition of aging that affects ... life. In a nine-year study that was a ... Research and the National Technical Institute for the Deaf ...
... 2012Targeted T-cells can seek out and destroy tumor cells ... that take advantage of this T-cell response are described ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Gene Therapy website at http://www.liebertpub.com/hum . ...
Cached Biology News:Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 2Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 3Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 4Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 5USF researchers identify gene mutation linked to old age hearing loss 2New anti-tumor cell therapy strategies are more effective 2
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
Biology Products: